Prevotella-Derived Butyrate Inhibits CD8+ T-Cell Glycolysis via AKT/mTOR Signalling to Alleviate MASH [0.03%]
Feixiang Xiong,Fengna Yan,Yuyong Jiang et al.
Feixiang Xiong et al.
Background and aims: Metabolic associated steatohepatitis (MASH) is a critical stage of MAFLD, lacking effective therapies. Gut microbiota and their metabolites, particularly short-chain fatty acids (SCFAs), are increasin...
Prevalence and Characteristics of Hyperferritinemia in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Meta-Analysis [0.03%]
Matheus Souza,Luan C V Lima,Cristiane Alves Villela-Nogueira
Matheus Souza
Background & aims: Hyperferritinemia (HF), defined as elevated serum ferritin (SF) levels, can reflect iron stores and chronic inflammation. However, the prevalence and clinical features of HF in metabolic dysfunction-ass...
Disentangling the Effect of BMI on Hepatocellular Carcinoma From Cirrhosis With Multivariable Mendelian Randomization [0.03%]
Apostolos Gkatzionis,Eleanor Sanderson,George Davey Smith et al.
Apostolos Gkatzionis et al.
Background & aims: While cirrhosis is a primary risk factor for hepatocellular carcinoma (HCC), a significant proportion of HCC cases attributed to metabolic dysfunction-associated steatotic liver disease (MASLD) develop ...
Continuous Versus Bolus Terlipressin for Acute Oesophageal Variceal Bleeding and Hepatorenal Syndrome in Cirrhosis: Meta-Analysis [0.03%]
Ping-Han Hsieh,Tsung-Chieh Yang,Enoch Yi-No Kang et al.
Ping-Han Hsieh et al.
Background & aims: Terlipressin is crucial for treating acute oesophageal variceal bleeding (AEVB) and hepatorenal syndrome (HRS). This meta-analysis compared the continuous versus bolus terlipressin infusion for treating...
Care Pathways for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A State-of-The-Art Review [0.03%]
Kirsi M A van Eekhout,Leonard D Broekman,Vivian D de Jong et al.
Kirsi M A van Eekhout et al.
Metabolic dysfunction-Associated Steatotic Liver Disease (MASLD) is a growing clinical challenge, necessitating effective diagnostic strategies to identify advanced liver fibrosis while minimising unnecessary referrals of mild cases. Curren...
Personalised Long-Term Albumin Treatment Based on Three-Month Ascites Response in Patients With Decompensated Cirrhosis [0.03%]
Enrico Pompili,Giulia Iannone,Salvatore Piano et al.
Enrico Pompili et al.
Background and aims: Long-term albumin (LTA) is effective for treating ascites in decompensated cirrhosis. This study aims to analyse the clinical courses of patients receiving LTA and provide a 3 month stratification to ...
Bridging Critically Ill Patients With Cirrhosis to Transplant With Renal Replacement Therapy: A Multicenter Cohort Study [0.03%]
Filipe S Cardoso,Minjee Kim,Beverley Kok et al.
Filipe S Cardoso et al.
Background & aims: The efficacy of renal replacement therapy (RRT) in critically ill patients with cirrhosis remains dubious. We aimed to assess the impact of RRT on these patients' outcomes. ...
Benedikt Silvester Hofer,Thomas Reiberger,Thomas Gremmel
Benedikt Silvester Hofer
Primary Biliary Cholangitis Increases Mortality Irrespective of Presence or Absence of Cirrhosis [0.03%]
Lars Bossen,Henning Grønbæk,Peter Ott et al.
Lars Bossen et al.
Background & aims: Primary biliary cholangitis (PBC) is an autoimmune liver disease whose effect on long-term survival remains unclear. We aimed to compare the prognosis of patients with biopsy-confirmed PBC with populati...
MASLD Is Associated With Decreased General Health Perception, Quality of Life and Work Productivity in a Low Fibrosis Population [0.03%]
L J M Heyens,C Van Steenkiste,M Struyve et al.
L J M Heyens et al.
Background: Data on quality of life in a low fibrosis prevalence metabolic dysfunction-associated steatotic liver disease (MASLD) cohort are scarce, as previous research has focused on advanced fibrosis and cirrhosis. Thi...